Sei Investments Co. Has $28.37 Million Stock Position in Sanofi $SNY

Sei Investments Co. decreased its stake in shares of Sanofi (NASDAQ:SNY) by 4.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 588,729 shares of the company’s stock after selling 27,582 shares during the period. Sei Investments Co.’s holdings in Sanofi were worth $28,366,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of SNY. Advisory Services Network LLC boosted its position in shares of Sanofi by 1.4% in the 3rd quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after purchasing an additional 210 shares during the last quarter. Savant Capital LLC lifted its holdings in Sanofi by 2.7% during the fourth quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock worth $418,000 after acquiring an additional 225 shares in the last quarter. Wesbanco Bank Inc. lifted its holdings in Sanofi by 4.9% during the fourth quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock worth $239,000 after acquiring an additional 230 shares in the last quarter. IFG Advisory LLC grew its stake in Sanofi by 2.7% in the fourth quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock valued at $446,000 after acquiring an additional 244 shares during the period. Finally, Cohen Investment Advisors LLC grew its stake in Sanofi by 2.9% in the first quarter. Cohen Investment Advisors LLC now owns 9,480 shares of the company’s stock valued at $457,000 after acquiring an additional 263 shares during the period. Institutional investors own 14.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Argus upgraded Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Morgan Stanley set a $49.00 target price on Sanofi in a research note on Wednesday, July 8th. BNP Paribas Exane downgraded shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price on the stock. in a report on Monday, April 20th. Finally, Wall Street Zen lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, Sanofi presently has a consensus rating of “Hold” and an average target price of $49.50.

Sanofi Stock Performance

Shares of SNY opened at $44.00 on Tuesday. The stock has a market capitalization of $106.67 billion, a price-to-earnings ratio of 12.29, a PEG ratio of 1.10 and a beta of 0.34. Sanofi has a 12 month low of $40.89 and a 12 month high of $52.68. The firm has a fifty day simple moving average of $43.45 and a 200 day simple moving average of $45.31. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.